Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.68 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3619549 | 0.91 | HSD11B1 (0.70) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL3614418 | 0.88 | HSD11B1 (0.63) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL3252937 | 0.88 | HSD11B1 (0.63) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL3615845 | 0.86 | HSD11B1 (0.61) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL3613702 | 0.86 | HSD11B1 (0.59) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL3620848 | 0.85 | HSD11B1 (0.60) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL3622062 | 0.85 | HSD11B1 (0.62) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL5830646 | 0.85 | HSD11B1 (0.50) | HSD11B1KMT2AMEN1PRKCZALDH1A1 | |
| SCHEMBL3622071 | 0.85 | HSD11B1 (0.59) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 | |
| SCHEMBL3610295 | 0.84 | HSD11B1 (0.57) | HSD11B1HSD17B1HSD17B2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2010-05-06 | — | — | US | claimed |
| US-7618961-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2009-11-17 | — | — | US | claimed |
| EP-1638553-A1 | NEW USE I | BIOVITRUM AB (SE) | 2006-03-29 | — | — | EP | claimed |
| WO-2004112784-A1 | NEW USE I | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | claimed |
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2010-05-06 | — | — | US | disclosed |
| US-7618961-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2009-11-17 | — | — | US | disclosed |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885 |
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD3B1 | HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.